June 2017 marks National Migraine Awareness Month (#MHAM). This month long series of events promotes education, collaboration and general consciousness enhancing regarding the neurological affliction, migraine disease.
Enormous strides have been made over the last several years. Possibly 2017 will be the most significant year to date, since the advent of triptans in 1991, in the history of migraine treatment. Research tells us we are on the cusp of emerging treatments designed to mark the processes in the brain and critical nerve pathways that trigger migraine attacks and the related symptoms that accompany these attacks, not the least of which is excruciating pain. At the clinical trials finish line: four major pharmaceutical companies are developing monoclonal antibodies that target CGRP and its receptors. Additionally, in development are other small molecular drugs that also target CGRP and other receptors that are known to be critical in alleviating the pain and related symptoms that associate with migraine. Cluster headaches may also respond. Perhaps now, with evidence based research, migraine and its variants will be viewed as a neurological disease, and in doing so, much of the stigma should be lost.
With these exciting research advances as a backdrop,the Association of Migraine Disorders is planning several events to underscore the importance of continuing and increasing the research and educational efforts to work towards a cure. Specifically, the Migraine Awards Dinner, to be held at the Squantum Association, in East Providence, Rhode Island on Friday, June 23rd, and the Shades for Migraine campaign and Migraine World Solidarity Day on June 21.
The Migraine Awards Dinner, our signature, annual fundraiser, apart from being a great evening of food and music, offers much in the in the area of migraine education and personal recognition.This year, prior to the actual event, we are holding a "Hot Topics In Migraine", panel discussion with migraine experts discussing current issues of the day. This part of the Event is free and open to the public. In a later portion of event, AMD recognizes several migraine research and advocacy luminaries with three special awards:
AMD Special Advocacy Award - Senator Sheldon Whitehouse - U.S. Senator, a lead co-sponsor of CARA (Comprehensive Addiction and Recovery Act) which was the vehicle the carried the STOP Pain provisions so important in migraine research funding.
AMD Innovation Award - Dale Bond, PhD - Is a Brown University Professor and researcher who studies the effects of behavioral weight loss interventions on migraine disease, a cutting edge topic.
AMD Impact Award - Katie Golden - Professional Patient, Writer for Migraine.com, Blogger at GoldenGraine.com, US Pain Ambassador, Patient Advocate, Speaker & Freelance Writer